Phase 3 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with squamous cell carcinoma of the esophagus, confirmed through a tissue biopsy
• People whose cancer was classified as stage I to IVA (where surgery was not possible or was declined) or stage IVB esophageal cancer that had spread only to lymph nodes near the collarbone, before treatment began
• People who completed a full course of combined chemotherapy and radiation therapy (chemoradiotherapy) without the cancer getting worse during treatment; radiation must have been delivered at a specific dose (50–50.4 Gy) using a precise technique, with specific chemotherapy drugs used alongside it; up to 4 cycles of chemotherapy before radiation are allowed; certain immunotherapy drugs were permitted during earlier treatment phases; no additional treatment after chemoradiotherapy
• People who are enrolling between 1 and 42 days after finishing chemoradiotherapy
• People aged 18 to 75 years
• People with an estimated life expectancy of more than 6 months
• People who are generally able to carry out daily activities, with limited physical limitations (confirm with trial site what this means for individual circumstances)
• People whose blood counts and organ function meet specific minimum requirements, including healthy enough levels of white blood cells, neutrophils, platelets, haemoglobin, albumin, liver enzymes, bilirubin, and kidney function
• People who are able to understand the trial details and have signed a written consent form

Who may not be able to join:

• People who have received any additional cancer treatment (such as chemotherapy, surgery, immunotherapy, or targeted therapy) after finishing chemoradiotherapy
• People whose cancer had spread to solid organs such as the liver, bones, lungs, or brain at the time of their original diagnosis
• People with a known or suspected allergy to the trial drug or any related medications
• People who have an esophageal fistula (an abnormal opening in the food pipe) or bleeding from the esophagus before joining
• People whose cancer has gotten worse after chemoradiotherapy
• People who developed moderate or severe radiation-related lung inflammation (pneumonitis) before enrolling
• People who experienced a serious (grade 3 or higher) immune-related side effect from previous treatment
• People who have previously been treated with targeted therapy drugs
• People with a history of another cancer, except for certain types that are considered low-risk or cured, such as non-melanoma skin cancer, early cervical carcinoma in situ, papillary thyroid cancer, or early-stage prostate cancer that has been cured
• People with serious heart, lung, liver, or kidney problems, blood disorders, severe malnutrition (cachexia), or other conditions that make chemotherapy unsafe
• People who are pregnant or breastfeeding
• People who are unable to give informed consent due to psychological, family, social, or other reasons
• People with moderate or severe nerve damage in the hands or feet (peripheral neuropathy, grade 2 or higher)
• People who have had diabetes for more than 10 years and whose blood sugar levels are poorly controlled
• People with a history of autoimmune diseases (such as lupus, rheumatoid arthritis, or colitis), immune system deficiencies (including HIV), or a history of organ or bone marrow transplant
• People with a history of interstitial lung disease or non-infectious pneumonia
• People with active hepatitis B or hepatitis C infections above certain measurable levels
• People with any unstable health condition that could put their safety or ability to participate in the trial at risk

Important: Always verify eligibility with the trial site directly before applying.